INmune Bio Announces Upcoming Presentations at CTAD
INmune Bio, Inc. (NASDAQ: INMB), a pioneering clinical-stage company focusing on inflammation and immunology, is set to make waves at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD) happening soon. This significant event will occur in San Diego, spanning from December 1 to December 4, and will feature two vital presentations that explore groundbreaking research in Alzheimer's treatment.
Key Presentation Details
The two presentations from INmune Bio will delve into pivotal studies that could shape the future of Alzheimer’s research.
XPro1595: A Promising Approach for Alzheimer’s Disease
The first presentation will cover XPro1595, known as a selective soluble TNF neutralizer, which has shown promising results in treating early Alzheimer's disease marked by inflammation (ADi). This presentation will unfold from the Phase 2 MINDFuL trial.
**Title:** XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial
**Date:** The discussions commence on December 1 and continue until December 2.
**Time:** The session is scheduled from 3:30 PM on December 1 to 5:30 PM on December 2, Pacific Time.
**Location:** P057
**Presenting Author:** Dr. Kim A. Staats from INmune Bio will lead this presentation.
Validation of Early Cognitive Metrics
The second presentation will highlight the validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC), linking its findings with blood-based biomarkers of Alzheimer’s disease.
**Title:** Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease
**Date:** This important presentation is set for December 4.
**Time:** Engaging discussions will be held from 7:15 AM until 5:00 PM, Pacific Time.
**Location:** P316
**Presenting Author:** Dr. Sarah Barnum from Cognition Metrics will present key findings.
About INmune Bio Inc.
INmune Bio Inc. operates within the biotech sector, tirelessly working to develop innovative treatments aimed at immunological and inflammatory responses. The company boasts a trifecta of product platforms:
- The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform harnesses advanced technology to selectively neutralize soluble TNF, a significant contributor to innate immune dysfunction.
- CORDStrom™ represents a breakthrough in using pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cells (hucMSCs), based on recent trials dedicated to addressing recessive dystrophic epidermolysis bullosa.
- INKmune® is designed to activate a patient’s natural killer cells, aiding in the elimination of minimal residual disease in cancer patients, currently being evaluated in a trial focused on metastatic castration-resistant prostate cancer.
For more information about their innovative approaches and ongoing research, feel free to visit www.inmunebio.com.
Frequently Asked Questions
What is the CTAD conference?
The Clinical Trials on Alzheimer’s Disease (CTAD) conference focuses on the latest advancements and research in Alzheimer's disease.
Who is presenting for INmune Bio?
Dr. Kim A. Staats and Dr. Sarah Barnum will present on behalf of INmune Bio.
What are the dates of the presentations?
The presentations will take place during the conference on December 1-4.
What is XPro1595?
XPro1595 is a selective soluble TNF neutralizer being studied as a treatment for early Alzheimer's disease.
How can I learn more about INmune Bio?
Visit INmune Bio's official website for detailed information regarding their research and products.